Sysmex (SSMXY) Projected to Release Quarterly Earnings on Wednesday

Sysmex (OTCMKTS:SSMXY) is anticipated to post its results after the market closes on Wednesday, August 5th. Analysts expect the company to post earnings of $0.07 per share and revenue of $741.3960 million for the quarter. Sysmex has set its FY 2026 guidance at 0.370-0.370 EPS.

Sysmex (OTCMKTS:SSMXY) last posted its quarterly earnings results on Thursday, May 14th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.04 by ($0.02). The business had revenue of $877.92 million during the quarter, compared to analysts’ expectations of $862.45 million. Sysmex had a net margin of 7.13% and a return on equity of 7.23%. On average, analysts expect Sysmex to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Sysmex Price Performance

SSMXY opened at $9.97 on Monday. The company has a quick ratio of 2.46, a current ratio of 3.26 and a debt-to-equity ratio of 0.12. Sysmex has a 52-week low of $8.01 and a 52-week high of $16.83. The company has a 50 day moving average of $9.22 and a two-hundred day moving average of $9.06. The company has a market cap of $6.28 billion, a P/E ratio of 26.24 and a beta of 1.05.

Analysts Set New Price Targets

Separately, Zacks Research lowered shares of Sysmex from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 14th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Sysmex presently has an average rating of “Hold”.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.